What is NDC 71287-119?

71287-119 is the product NDC for Yescarta (axicabtagene ciloleucel), Axicabtagene ciloleucel 2000000 1/68mL suspension, listed with the FDA by Kite Pharma, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Yescarta (Axicabtagene ciloleucel).

Kite Pharma, Inc., NDC labeler code 71287. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Yescarta?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Yescarta NDC 71287-119 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)71287-119Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71287-0119Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71287-119-02	71287011902	1 BAG in 1 PACKAGE (71287-119-02) / 68 mL in 1 BAG (71287-119-01)Marketed from Oct 18, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Yescarta
Generic name (nonproprietary): axicabtagene ciloleucel
Active ingredients: Axicabtagene ciloleucel — 2000000 1/68mL
Dosage form: Suspension
Route: Intravenous
Labeler: Kite Pharma, Inc.NDC labeler code 71287
Product type: Cellular therapy
Marketing category: BLA — Biologics License ApplicationApplication BLA 125643
Marketing start: Oct 18, 2017
Listing expires: Dec 31, 2027
Other FDA classes: CD19 Receptor Interactions (Mechanism)CD19-specific Chimeric Antigen Receptor (Chemical structure)Increased T Lymphocyte Activation (Physiologic effect)Genetically-modified (EXT)
Identifiers: Product ID 71287-119_23cad324-9e01-4dba-8152-354dadb7b1e5SPL ID 23cad324-9e01-4dba-8152-354dadb7b1e5SPL set ID 9b70606e-b99c-4272-a0f1-b5523cce0c59RxCUI 1987402, 1987407UNII U2I8T43Y7R
Pharmacologic class: CD19-directed Chimeric Antigen Receptor; Genetically-modified Autologous T Cells

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471287011902 followed by a unit qualifier and the quantity

Package 71287-0119-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. ( 1.1 ) Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71287-119

What is NDC 71287-119?: 71287-119 is the product NDC for Yescarta (axicabtagene ciloleucel), Axicabtagene ciloleucel 2000000 1/68mL suspension, listed with the FDA by Kite Pharma, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Yescarta (Axicabtagene ciloleucel).
What is the active ingredient?: Axicabtagene ciloleucel.
Who is the labeler?: Kite Pharma, Inc., NDC labeler code 71287. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Yescarta?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Yescarta (Axicabtagene ciloleucel) NDC 71287-119